Publicacións nas que colabora con Jose Luis Piñana Sánchez (14)

2022

  1. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

    Cancers, Vol. 14, Núm. 22

  2. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

    Cancers, Vol. 14, Núm. 11

  3. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

  2. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  3. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

    Bone Marrow Transplantation

2018

  1. CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome 

    Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 5, pp. 964-972

  2. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting

    Medical Oncology, Vol. 35, Núm. 6

2017

  1. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation

    Bone Marrow Transplantation

2016

  1. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815

  2. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study

    Bone Marrow Transplantation

2012

  1. Evaluation of prognostic factors among patients with chronic graft-versus-host disease

    Haematologica, Vol. 97, Núm. 8, pp. 1187-1195

2010

  1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long-term follow-up from two prospective multicenter trials

    Haematologica, Vol. 95, Núm. 7, pp. 1176-1182

2008

  1. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival

    Journal of Clinical Oncology, Vol. 26, Núm. 4, pp. 577-584